Abstract
The decentralisation of the Spanish healthcare system and the large number of
different hospital operators mean that the market is both fragmented and
regionalised. Healthcare provision is through a mixture of public and private
facilities. This report is ideal for executives wanting to understand the key
drivers in the medical market and have access to a wealth of statistical data,
including five-year market projections. Included with the report are 3 free
quarterly updated outlook reports, enabling you to keep up to date with market
developments for a year.
The Spanish healthcare system faces further upheaval as administrative and
financial responsibility for healthcare services is finally being transferred
to those regions previously administered centrally. Despite increased
investment in healthcare in recent years, which has boosted per capita
healthcare expenditure to over US$1,000, funding for the national health
service remains tight, and the government has acknowledged that public health
expenditure needs to rise by a further 1.0% of GDP, from the current 7.7%, in
order to meet demand. Per capita spending on medical equipment in Spain is on
the low side for an EU country; the level is similar to Greece, Portugal or
the Czech Republic. Most of the market is supplied by imports, mainly from the
USA and other EU-15 countries.
The decentralisation of the Spanish healthcare system and the large number of
different hospital operators mean that the market is both fragmented and
regionalised. Healthcare provision is through a mixture of public and private
facilities. INSALUD is a centralised health system that operates facilities
Ceuta and Melilla in Morocco. Spain has a strong medical device manufacturing
sector, which tends to be based around Barcelona. Companies, however, tend to
be small and concentrated at the low to medium technology end of the market.
Distribution of medical products is primarily carried out by multinational
subsidiaries and a large number of small family-owned regional distributors,
each with revenues of under US$10 million. These are estimated to account for
around 75% of the total market. The remaining 25% is covered by six larger
distribution companies (Grupo Taper, Prim, Cormedica, Palex, MAB, Izasa),
which operate on a national scale. There are signs that the larger
distribution companies are gaining market share as lengthy delays in payment
by public health service operators force out smaller companies.
View Cart
